The Effects of a Novel Probiotic on Gastrointestinal Health in Generally Healthy Adults

Gastrointestinal Health Clinical Trial

Official title:

A Randomized, Parallel, Double-blind, Placebo-Controlled Study to Investigate the Effects of a Novel Probiotic on Gastrointestinal Health in Generally Healthy Adults

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05595980
• Other study ID #: BIO-2210
• Status: Completed
• Phase: N/A
• Start date: September 19, 2022
• Est. completion date: February 3, 2023

Study information

• Verified date: February 2023
• Source: BIO-CAT Microbials, LLC
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The primary objective of this study is to investigate the effect of an oral probiotic (Bacillus sp. spore preparation) on abdominal bloating, flatulence, and burping in generally healthy adults. Secondary outcomes include intestinal barrier integrity and fecal microbiome properties (taxonomical structure, diversity, and function).

Description:

Probiotics are live microbes that, when administered in adequate amounts, confer a health benefit. Examples of probiotic health benefits include the support of gastrointestinal (GI) health and immune health. Common probiotic strains include species from the Bacillaceae family (e.g. Bacillus genus) and Lactobacillaceae family of the Bacillota phylum (formerly Firmicutes), and species from the Bifidobacterium genus of the Actinomycetota phylum (formerly Actinobacteria). Bacillaceae species are particularly advantageous for oral probiotic applications because they can be manufactured as spores with highly proteinaceous coats that persist without refrigeration and resist the acidic and high bile salt conditions that occur across the human GI tract. The objective of this clinical study is to investigate the effects of daily oral supplementation with a novel Bacillus sp. spore preparation for 8 weeks on GI symptoms, intestinal barrier integrity, and fecal microbiome properties. This will be a randomized, parallel, double-blind, placebo-controlled study consisting of one screening visit (Visit 1, Day -7) and four study visits (Days 0, 1, 57, and 58). At Visit 1 (Day -7), participants will arrive at the clinic in a fasting state (≥ 10 hours). After participants provide voluntary informed consent, participants will undergo medical history, prior and current medication/supplement use, and inclusion and exclusion criteria assessments. Additionally, height, body weight, and vital signs will be measured, and body mass index (BMI) will be calculated. Blood samples will be collected for chemistry, hematology, C-reactive protein (CRP), and insulin analyses. Participants will be dispensed a daily paper Gastrointestinal Tolerance Questionnaire (GITQ) with instructions to capture events occurring during the seven continuous days prior to Visit 2 (Day 0). The paper GITQ contains a series of questions regarding the presence and severity of GI symptoms occurring during the past 24 hours. Therefore, participants will be instructed to complete their first GITQ on the morning of Day -6 and the final GITQ on the morning of Day 0, just before their Visit 2. Additionally, a stool sample collection kit will be dispensed with instructions to a collect stool sample from a single bowel movement (for fecal microbiome analyses) within the 3 days immediately before Visit 2 (Day 0). At Visit 2 (Day 0), participants will arrive at the clinic in a fasting state (≥ 10 hours). Participants will undergo clinic visit procedures (concomitant medication/supplement use, assess inclusion/exclusion criteria, body weight, and vital signs measurements) and adverse event (AE) assessment. Fecal samples will be collected, and subjects will be administered a 7-day recall GITQ. Participants will then undergo an intestinal permeability test where they will ingest four sugar probes (1 g mannitol, 1 g sucralose, 1 g erythritol, and 5 g lactulose) in approximately 240 mL water. Participants will be dispensed 2 separate containers to collect all urine over the following 24 hours, with urine collected from 0 to 5 hours in one container and from 5 to 24 hours in the second container. Participants will be instructed to return both containers to the clinic the following day at Visit 3 (Day 1). Upon completion of the GI permeability test, participants will be randomly assigned to a study product sequence. Participants will receive an email link for an electronic 7-day recall GITQ to be completed on Days 8, 15, 22, 29, 36, 43, 50, and 57. Participants will also receive information regarding daily links that will be sent via email to complete electronic 24-hour recall GITQs and will be instructed to complete these electronic 24-hour GITQs daily starting on day 51, which will be 6 days ahead of Visit 4. Participants will continue recording the 24-hour GITQ recall every day for seven total days (Days 51, 52, 53, 54, 55, 56, and 57). Additionally, a stool sample collection kit will be dispensed with instructions to collect a stool sample from a single bowel movement for fecal microbiome analyses within the 3 days immediately before Visit 4 (Day 57). In addition, a subset of male subjects will be selected to collect an additional fecal sample for fecal metabolomic and/or targeted analyte analyses. At Visit 3 (Day 1), participants will return the 24-hour urine sample collection containers and undergo AE assessments. Participants will be dispensed their assigned study product and will be instructed to consume it once a day (1 capsule/d) with their meal that is typically the largest of the day for 56 days starting on Day 1. At Visit 4 (Day 57), participants will arrive at the clinic fasted (≥ 10 hours) and undergo clinic visit procedures, including: concomitant medication/supplement use, review inclusion/exclusion criteria, body weight and vital signs measurements, and AE assessment. Fecal samples will be collected. Blood samples will be collected for chemistry, hematology, CRP, and insulin analyses. Participants will then complete the intestinal permeability test with the same procedures and study instructions described at Visit 2. At Visit 5 (Day 58), participants will return the 24-hour urine sample collection containers and undergo AE assessments.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 80
• Est. completion date: February 3, 2023
• Est. primary completion date: February 3, 2023
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 30 Years to 65 Years

Eligibility

Inclusion Criteria:

1. Male or female, 30-65 years of age, inclusive at Visit 1 (Day -7)

2. BMI of 18.50 to 31.99 kg/m^2, inclusive, at Visit 1 (Day -7)

3. Have = 3 weekly total symptom score obtained by combining ratings for gas/flatulence, abdominal bloating, and burping symptoms (e.g., 3 days with a mild severity across the three symptoms, 1 day of mild severity and 1 day of moderate severity across the three symptoms, or 1 day of severe severity across the three symptoms)

4. Consumes a typical American diet (defined as = 3 servings/d of fruits and vegetables combined and < 3 servings/d of whole grains)

5. Non-user of tobacco or nicotine products (e.g., cigarette smoking, vaping, chewing tobacco) with no plans to begin use during the study period

6. Non-user or former users (cessation = 12 months) of any marijuana or hemp products and has no plans to use marijuana or hemp products during the study period

7. Willing to maintain physical activity and exercise patterns, body weight, and habitual diet throughout the trial

8. Willing to limit alcohol consumption to = 2 standard drinks per day throughout the trial

9. Willing to refrain from exclusionary medications, supplements, and products throughout the study

10. No health conditions that would prevent him/her from fulfilling the study requirements as judged by the Clinical Investigator on the basis of medical history and routine laboratory test results

11. Understands the study procedures and signs forms providing informed consent to participate in the study and authorizes the release of relevant protected health information to the Clinical Investigator

Exclusion Criteria:

1. Known sensitivity, intolerability, or allergy to any of the study products or their excipients

2. Abnormal laboratory test results of clinical significance at Visit 1 (Day -7), at the discretion of the Clinical Investigator

3. Clinically important GI condition that would potentially interfere with the evaluation of the study product (e.g., inflammatory bowel disease, irritable bowel syndrome, gastric reflux, indigestion, dyspepsia, Crohn's disease, celiac disease, history of surgery for weight loss, gastroparesis, and clinically significant lactose or gluten intolerance or other food or ingredient allergies)

4. Pre-menopausal female subject with an irregular menstrual cycle (regular cycle defined as 21 to 35 days in length for the last 3 months prior to Visit 1)

5. Recent (within 2 weeks of Visit 1; Day -7) history of an episode of acute GI illness such as nausea/vomiting or diarrhea (defined as = 3 loose or liquid stools/d)

6. Self-reported history (within 6 weeks of Visit 1; Day -7) of constipation (defined as fewer than three bowel movements per week)

7. Uncontrolled and/or clinically important pulmonary (including uncontrolled asthma), cardiac (including, but not limited to, atherosclerotic disease, history of myocardial infarction, peripheral arterial disease, stroke), hepatic, renal, endocrine (including Type 1 and Type 2 diabetes mellitus), hematologic, immunologic, neurologic (such as Alzheimer's or Parkinson's disease), psychiatric (including depression and/or anxiety disorders) or biliary disorders. Conditions which are well-controlled or resolved will be assessed by the Clinical Investigator on a case-by-case basis.

8. Uncontrolled hypertension (systolic blood pressure = 140 mm Hg or diastolic blood pressure = 90 mm Hg) as defined by the blood pressure measured at Visit 1 (Day -7)

9. Have received a COVID-19 vaccine within 2 weeks of randomization or expected to receive a COVID-19 vaccine during the study period

10. Had a positive SARS-CoV2 test and experienced symptoms for > 2 months (i.e. "long-haulers")

11. Known allergy, intolerances or sensitivity to milk, soy, or wheat

12. Extreme dietary habits at the discretion of the Clinical Investigator

13. History or presence of cancer in the prior 2 years, except for non-melanoma skin cancer

14. Major trauma or any other surgical event within 3 months of Visit 1 (Day -7)

15. Signs or symptoms of an active infection of clinical relevance within 5 days of Visit 1 (Day -7)

16. Weight loss or gain > 4.5 kg in the 3 months prior to Visit 1 (Day -7)

17. Currently or planning to be on a weight loss regimen during the study

18. Antibiotic use within 3 months of Visit 1 (Day -7) and throughout the study period

19. Use of steroids within 1 month of Visit 1 (Day -7) and throughout the study period

20. Chronic use (i.e., daily on a regular basis) of anti-inflammatory medications (e.g., NSAIDS) within 1 month of Visit 1 (Day -7)

21. Use of medications (over-the-counter or prescription) and/or dietary supplements, known to influence GI function, including but not limited to, pre- and probiotic supplements as well as foods or beverages containing live probiotics (e.g., yogurt, kombucha), fiber supplements, laxatives, enemas, suppositories, H2 blockers, proton pump inhibitors, antacids, anti-diarrheal agents, anti-depressants, and/or anti-spasmodic within 2 weeks of Visit 1 (Day -7) and throughout the study period

22. Participated in endoscopy or endoscopy preparation within 3 months prior to Visit 1 (Day -7)

23. Exposure to any non-registered drug product within 4 weeks prior to Visit 1 (Day -7)

24. Female who is pregnant, planning to be pregnant during the study period, lactating, or is of childbearing potential and is unwilling to commit to the use of a medically approved form of contraception throughout the study period

25. Recent history (within 12 months of screening; Visit 1; Day -7) of alcohol or substance abuse

26. Self-report of blood donation totaling between 101 mL to 449 mL of blood within 30 days prior to screening or a blood donation of more than 450 mL within 56 days

27. Receipt or use of study products in another research study within 28 days prior to Visit 2 (Day 0) or longer if the previous study product is deemed by the Clinical Investigator to have lasting effects that might influence the eligibility criteria or outcomes of current study.

28. Has a condition the Clinical Investigator believes would interfere with his ability to provide informed consent, comply with the study protocol, which might confound the interpretation of the study results, or put the subject at undue risk

Related Conditions & MeSH terms

• Digestive Health
• Gastrointestinal Health
• Immune Health

Intervention

Dietary Supplement:
• Probiotic
Participants will consume 1 capsule containing 2 billion CFU of a Bacillus strain spore preparation once daily for 56 days
• Placebo
Participants will consume 1 capsule containing maltodextrin once daily for 56 days

Locations

Country	Name	City	State
United States	Biofortis Clinical Research, Inc.	Addison	Illinois

Sponsors (3)

Lead Sponsor	Collaborator
BIO-CAT Microbials, LLC	Biofortis Clinical Research, Inc., Ohio State University

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Fecal metabolome profile	Between placebo and probiotic treatments, the difference in the mass spectrometry-based fecal metabolome profiles at end of study (only for 16 to 20 male participants with BMI 25.00-31.99 kg/(m)^2)	Day 57
Primary	Composite score of abdominal bloating, flatulence, and burping (daily GITQ)	Between placebo and probiotic treatments, the difference in the proportion of participants with a decrease (indicating improvement) in the 7-day total composite score of abdominal bloating, flatulence, and burping, from baseline to week 8, where an increase in scores (indicating worsening) cannot occur within any of the 3 symptoms (daily Gastrointestinal Tolerance Questionnaire [GITQ])	9 weeks
Secondary	Composite score of abdominal bloating, flatulence, and burping (7-day recall GITQ)	Between placebo and probiotic treatments, the difference in the proportion of participants with a decrease in the 7-day total composite score of abdominal bloating, flatulence, and burping, from baseline to week 8 (7-day recall GITQ)	9 weeks
Secondary	Composite score of 8 GI symptoms (daily GITQ)	Between placebo and probiotic treatments, the difference in the proportion of participants with a decrease in the 7-day total composite score of abdominal bloating, flatulence, burping, nausea, vomiting, abdominal cramping, stomach rumbling, and reflux, from baseline to week 8 (daily GITQ)	9 weeks
Secondary	Composite score of 8 GI symptoms (7-day recall GITQ)	Between placebo and probiotic treatments, the difference in the proportion of participants with a decrease in the 7-day total composite score of abdominal bloating, flatulence, burping, nausea, vomiting, abdominal cramping, stomach rumbling, and reflux, from baseline to week 8 (7-day recall GITQ)	9 weeks
Secondary	Individual GI symptom scores (daily GITQ)	Between placebo and probiotic treatments, the difference in the proportion of participants with a decrease in 7-day individual symptom scores from baseline to week 8, for each of abdominal bloating, flatulence, burping, nausea, vomiting, abdominal cramping, stomach rumbling, and reflux (daily GITQ)	9 weeks
Secondary	Individual GI symptom scores (7-day recall GITQ)	Between placebo and probiotic treatments, the difference in the proportion of participants with a decrease in 7-day individual symptom scores from baseline to week 8, for each of abdominal bloating, flatulence, burping, nausea, vomiting, abdominal cramping, stomach rumbling, and reflux (7-day recall GITQ)	9 weeks
Secondary	Composite score of abdominal bloating, flatulence, and burping (interim weeks)	Between placebo and probiotic treatments, the difference in the proportion of participants showing a decrease in the 7-day total composite score of abdominal bloating, flatulence, and burping, from baseline to each measured, interim time point (i.e., week 1, week 2, week 3, week 4, week 5, week 6, week 7) (7-day recall GITQ)	2 - 8 weeks
Secondary	Individual GI symptom scores (interim weeks)	Between placebo and probiotic treatments, the difference in the proportion of participants showing a decrease in the 7-day individual symptom scores for each of abdominal bloating, flatulence, burping, nausea, vomiting, abdominal cramping, stomach rumbling, and reflux, from baseline to each measured, interim time point (i.e., week 1, week 2, week 3, week 4, week 5, week 6, week 7) (7-day recall GITQ)	2 - 8 weeks
Secondary	Small intestinal permeability	Between placebo and probiotic treatments, the difference in small intestinal permeability from baseline to Day 57 (0 to 5 hour urinary lactulose:mannitol ratio)	8 weeks
Secondary	Colonic permeability	Between placebo and probiotic treatments, the difference in colonic permeability from baseline to Day 57 (5 to 24 hour urinary sucralose:erythritol ratio)	8 weeks
Secondary	Gut permeability	Between placebo and probiotic treatments, the difference in gut permeability from baseline to Day 57 (0 to 24 hour urinary sucralose:erythritol ratio)	8 weeks
Secondary	Fecal microbiome profile	Between placebo and probiotic treatments, the difference in "shotgun" metagenomic sequencing-based fecal microbiome profiles from baseline to Day 57	8 weeks
Secondary	Fecal microbiome profile	Between placebo and probiotic treatments, the difference in "shotgun" metagenomic sequencing-based fecal microbiome profiles at end of study	Day 57
Secondary	Plasma C-reactive protein	Between placebo and probiotic treatments, change from baseline to week 8 in fasting blood C-reactive protein concentration (mg/L)	9 weeks
Secondary	Serum insulin	Between placebo and probiotic treatments, change from baseline to week 8 in fasting serum insulin concentration (mIU/L)	9 weeks
Secondary	Safety: Albumin	Fasting plasma albumin concentration (g/dL)	9 weeks
Secondary	Safety: Alkaline phosphatase	Fasting plasma alkaline phosphatase concentration (U/L)	9 weeks
Secondary	Safety: Alanine aminotransferase	Fasting plasma alanine aminotransferase concentration (U/L)	9 weeks
Secondary	Safety: Anion gap	Fasting plasma anion gap (nmol/L)	9 weeks
Secondary	Safety: Aspartate aminotransferase	Fasting plasma aspartate aminotransferase concentration (U/L)	9 weeks
Secondary	Safety: Blood urea nitrogen	Fasting blood urea nitrogen concentration (mg/dL)	9 weeks
Secondary	Safety: Osmolality	Fasting plasma osmolality (mOsm/kg)	9 weeks
Secondary	Safety: Calcium	Fasting plasma total calcium concentration (mg/dL)	9 weeks
Secondary	Safety: Chloride	Fasting plasma chloride concentration (mmol/L)	9 weeks
Secondary	Safety: Carbon dioxide	Fasting plasma carbon dioxide concentration (mmol/L)	9 weeks
Secondary	Safety: Creatinine	Fasting plasma creatinine concentration (mg/dL)	9 weeks
Secondary	Safety: Globulin	Fasting plasma globulin concentration (g/dL)	9 weeks
Secondary	Safety: Glucose	Fasting plasma glucose concentration (mg/dL)	9 weeks
Secondary	Safety: Potassium	Fasting plasma potassium concentration (mmol/L)	9 weeks
Secondary	Safety: Sodium	Fasting plasma sodium concentration (mmol/L)	9 weeks
Secondary	Safety: Total bilirubin	Fasting plasma total bilirubin concentration (mg/dL)	9 weeks
Secondary	Safety: Total protein	Fasting plasma total protein concentration (g/dL)	9 weeks
Secondary	Safety: Basophils	Fasting plasma basophil count	9 weeks
Secondary	Safety: Eosinophils	Fasting plasma eosinophil count	9 weeks
Secondary	Safety: Hematocrit	Fasting hematocrit (as volume percent)	9 weeks
Secondary	Safety: Hemoglobin	Fasting plasma hemoglobin concentration (g/dL)	9 weeks
Secondary	Safety: Lymphocytes	Fasting plasma lymphocyte count	9 weeks
Secondary	Safety: Mean corpuscular hemoglobin	Fasting plasma mean corpuscular hemoglobin (pg)	9 weeks
Secondary	Safety: Mean corpuscular hemoglobin concentration	Fasting plasma mean corpuscular hemoglobin concentration (g/dL)	9 weeks
Secondary	Safety: Mean corpuscular volume	Fasting plasma mean corpuscular volume (fL)	9 weeks
Secondary	Safety: Monocytes	Fasting plasma monocyte count	9 weeks
Secondary	Safety: Neutrophils	Fasting plasma neutrophil count	9 weeks
Secondary	Safety: Platelets	Fasting plasma platelet count	9 weeks
Secondary	Safety: Red blood cells	Fasting plasma red blood cell count	9 weeks
Secondary	Safety: White blood cells	Fasting plasma white blood cell count	9 weeks
Secondary	Safety: Blood pressure	Resting systolic blood pressure over resting diastolic blood pressure (mmHg/mmHg)	9 weeks
Secondary	Safety: Heart rate	Resting heart rate (beats per minute)	9 weeks
Secondary	Safety: Incidence of adverse events	Number of participants with self-reported adverse events	9 weeks